Cancer of Liver
Conditions
Keywords
Hepatoma, Transcatheter Arterial chemo-embolization, Microsphere, Doxorubicin
Brief summary
The purpose of this study is to evaluate the safety and efficacy of Radiopaque Microsphere (T-ACE Beads with doxorubicin) interventional therapy for patients with liver cancer
Detailed description
The study will evaluate the safety and tolerability of Taiwan ACE Beads with doxorubicin used for chemoembolization for the treatment of unresectable hepatocellular carcinoma. The investigators will study the overall response rates of lesions with Taiwan ACE Beads. The procedure is similar with the other commercializing drug-eluting beads. At the target vessels, radiologists will inject doxorubicin with Taiwan ACE Beads instead of Gelfoam or PVA (polyvinyl alcohol). The end point of injection is also similar with conventional TACE. Determine the complication rates, progression free survival (PFS) and overall survival (OS) following Taiwan ACE Beads embolization.
Interventions
DEVICETaiwan ACE Beads with doxorubicin
Similar with commercializing drug-eluting beads, radiologist inject Taiwan ACE Beads with doxorubicin instead of Gelfoam or polyvinyl alcohol.
Sponsors
The Industrial Technology Research Institute
National Cheng Kung University
National Cheng-Kung University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must meet all of the following inclusion criteria in order to be entered into the study: A. Both genders of patients age 20 or older. B. Patients diagnosed of liver cancer (MUST meet at least ONE of the following criteria:) 1. Diagnosed via tumor biopsy by Pathologists, and confirmed by on-service physician. 2. High risk patients (Viral hepatitis B or C or cirrhotics) with typical liver cancer image appeared on more than two radiographic examinations (Ultrasound, MRI, CT scan or Angiography). 3. High risk patients (Viral hepatitis B or C cirrhotics) with evidence of enlarging image of liver cancer via more than two follow-up records. C. In intermediate stage by BCLC staging, tumor size under 8 centimeters, with liver function at Child-Pugh class ≤ 8, and is either difficult to accept an operation or reluctant to accept any operation. D. Disease can be treated by transarterial chemoembolization, and can be evaluated by Ultrasound, Magnetic resonance imaging (MRI), or computed tomography (CT). E. Performance status ECOG 2 or less. Patient has a life expectancy of at least 3 months.
Exclusion criteria
If patients meet any of the following criteria they may not be entered into the study: A. major branch of portal vein has been invaded already; extrahepatic metastasis or the the other malignant tumors. B. Evidences of decompensation: Total Bilirubin\>2, PT prolong\>3 seconds, Child-Pugh class\>8, refractory ascites, active bleeding, hepatic encephalopathy, and severe infection. C. Tumor size (diameter) larger than 8 centimeters. D. Not on dialysis with Creatinine \>2.0 mg/dL. E. Allergic to iodine or other injections. F. Other main organ failure (Heart, Lung, or Kidney). G. WBC\<3000, or Platelet Count \<50,000 mg/dL. H. Performance status ECOG of 3 or more. I. Pregnant women and breath feeding women. J. Patients whose blood vessel are too difficult to do Taiwan ACE Beads procedure. K. Prominent AV shunt. L. Severe atherosclerosis. M. Vasospasm or possible major vascular injury. N. Arteriovenous shunt patients, diameter larger than the size of microsphere available. O. Collateral vascular exists and may endanger non-targeted area during arterial chemoembolization. P. Contraindications for doxorubicin. Q. Numerous of tumors locate at different lobes, high risk of Hepatic insufficiency. R. Unwilling to sign a written informed consent form. S. Allergic to pharmaceutical excipients related to Microspheres.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patients Survival (Safety) | An average of 12 weeks. | Survival rate will be evaluated since treatment day until the date of death or final observation. |
| Tumor response in patients with hepatoma who received Taiwan ACE beads (TACE) microspheres embolization evaluated with mRECIST criteria | Three months | mRECIST criteria will be used to evaluate tumor response in patients with hepatoma who received Taiwan ACE beads (TACE) microspheres embolization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum Level of AFP | An average of 12 weeks | Collect Doxorubicin's blood concentration, 5 mL each time |
Countries
Taiwan
Outcome results
None listed